PMID- 23312562
OWN - NLM
STAT- MEDLINE
DCOM- 20131028
LR  - 20211021
IS  - 1873-2402 (Electronic)
IS  - 0006-3223 (Print)
IS  - 0006-3223 (Linking)
VI  - 73
IP  - 11
DP  - 2013 Jun 1
TI  - The brain-derived neurotrophic factor Val66Met polymorphism predicts response to 
      exposure therapy in posttraumatic stress disorder.
PG  - 1059-63
LID - S0006-3223(12)01034-7 [pii]
LID - 10.1016/j.biopsych.2012.10.033 [doi]
AB  - BACKGROUND: The most effective treatment for posttraumatic stress disorder (PTSD) 
      is exposure therapy, which aims to facilitate extinction of conditioned fear. 
      Recent evidence suggests that brain-derived neurotrophic factor (BDNF) 
      facilitates extinction learning. This study assessed whether the Met-66 allele of 
      BDNF, which results in lower activity-dependent secretion, predicts poor response 
      to exposure therapy in PTSD. METHODS: Fifty-five patients with PTSD underwent an 
      8-week exposure-based cognitive behavior therapy program and provided mouth swabs 
      or saliva to extract genomic DNA to determine their BDNF Val66Met genotype (30 
      patients with the Val/Val BDNF allele, 25 patients with the Met-66 allele). We 
      examined whether BDNF genotype predicted reduction in PTSD severity following 
      exposure therapy. RESULTS: Analyses revealed poorer response to exposure therapy 
      in the PTSD patients with the Met-66 allele of BDNF compared with patients with 
      the Val/Val allele. Pretreatment Clinician Administered PTSD Scale severity and 
      BDNF Val66Met polymorphism predicted response to exposure therapy using 
      hierarchical regression. CONCLUSIONS: This study provides the first evidence that 
      the BDNF Val66Met genotype predicts response to cognitive behavior therapy in 
      PTSD and is in accord with evidence that BDNF facilitates extinction learning.
CI  - Copyright (c) 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All 
      rights reserved.
FAU - Felmingham, Kim L
AU  - Felmingham KL
AD  - School of Psychology, University of Tasmania, Hobart, TAS 7005, Australia. 
      Kim.Felmingham@utas.edu.au
FAU - Dobson-Stone, Carol
AU  - Dobson-Stone C
FAU - Schofield, Peter R
AU  - Schofield PR
FAU - Quirk, Gregory J
AU  - Quirk GJ
FAU - Bryant, Richard A
AU  - Bryant RA
LA  - eng
GR  - R01 MH081975/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130108
PL  - United States
TA  - Biol Psychiatry
JT  - Biological psychiatry
JID - 0213264
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - AE28F7PNPL (Methionine)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Implosive Therapy/*methods
MH  - Male
MH  - Methionine/genetics
MH  - Middle Aged
MH  - Polymorphism, Genetic/*genetics
MH  - Predictive Value of Tests
MH  - Regression Analysis
MH  - Stress Disorders, Post-Traumatic/*genetics/*rehabilitation
MH  - Trauma Severity Indices
MH  - Treatment Outcome
MH  - Valine/genetics
PMC - PMC4185184
MID - NIHMS481795
EDAT- 2013/01/15 06:00
MHDA- 2013/10/29 06:00
PMCR- 2014/10/04
CRDT- 2013/01/15 06:00
PHST- 2012/04/30 00:00 [received]
PHST- 2012/10/16 00:00 [revised]
PHST- 2012/10/16 00:00 [accepted]
PHST- 2013/01/15 06:00 [entrez]
PHST- 2013/01/15 06:00 [pubmed]
PHST- 2013/10/29 06:00 [medline]
PHST- 2014/10/04 00:00 [pmc-release]
AID - S0006-3223(12)01034-7 [pii]
AID - 10.1016/j.biopsych.2012.10.033 [doi]
PST - ppublish
SO  - Biol Psychiatry. 2013 Jun 1;73(11):1059-63. doi: 10.1016/j.biopsych.2012.10.033. 
      Epub 2013 Jan 8.